These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20351182)

  • 1. Notch2 signaling is required for potent antitumor immunity in vivo.
    Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
    J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic regulation of notch 1 and notch 2 surface expression during T cell development and activation revealed by novel monoclonal antibodies.
    Fiorini E; Merck E; Wilson A; Ferrero I; Jiang W; Koch U; Auderset F; Laurenti E; Tacchini-Cottier F; Pierres M; Radtke F; Luther SA; Macdonald HR
    J Immunol; 2009 Dec; 183(11):7212-22. PubMed ID: 19915064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
    Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch signaling confers antigen-presenting cell functions on mast cells.
    Nakano N; Nishiyama C; Yagita H; Koyanagi A; Akiba H; Chiba S; Ogawa H; Okumura K
    J Allergy Clin Immunol; 2009 Jan; 123(1):74-81.e1. PubMed ID: 19130928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity.
    Maekawa Y; Minato Y; Ishifune C; Kurihara T; Kitamura A; Kojima H; Yagita H; Sakata-Yanagimoto M; Saito T; Taniuchi I; Chiba S; Sone S; Yasutomo K
    Nat Immunol; 2008 Oct; 9(10):1140-7. PubMed ID: 18724371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 and Notch2 receptors influence progressive hair graying in a dose-dependent manner.
    Schouwey K; Delmas V; Larue L; Zimber-Strobl U; Strobl LJ; Radtke F; Beermann F
    Dev Dyn; 2007 Jan; 236(1):282-9. PubMed ID: 17080428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional ablation of Notch signaling in pancreatic development.
    Nakhai H; Siveke JT; Klein B; Mendoza-Torres L; Mazur PK; Algül H; Radtke F; Strobl L; Zimber-Strobl U; Schmid RM
    Development; 2008 Aug; 135(16):2757-65. PubMed ID: 18635610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis.
    Kumano K; Masuda S; Sata M; Saito T; Lee SY; Sakata-Yanagimoto M; Tomita T; Iwatsubo T; Natsugari H; Kurokawa M; Ogawa S; Chiba S
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):70-8. PubMed ID: 18353145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
    Simma O; Zebedin E; Neugebauer N; Schellack C; Pilz A; Chang-Rodriguez S; Lingnau K; Weisz E; Putz EM; Pickl WF; Felzmann T; Müller M; Decker T; Sexl V; Stoiber D
    Cancer Res; 2009 Jan; 69(1):203-11. PubMed ID: 19118004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
    Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
    Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.